Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

16 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Glioma oncogenesis in the Constitutional mismatch repair deficiency (CMMRD) syndrome.
Guerrini-Rousseau L, Merlevede J, Denizeau P, Andreiuolo F, Varlet P, Puget S, Beccaria K, Blauwblomme T, Cabaret O, Hamzaoui N, Bourdeaut F, Faure-Conter C, Muleris M, Colas C, Adam de Beaumais T, Castel D, Rouleau E, Brugières L, Grill J, Debily MA. Guerrini-Rousseau L, et al. Among authors: adam de beaumais t. Neurooncol Adv. 2024 Jul 11;6(1):vdae120. doi: 10.1093/noajnl/vdae120. eCollection 2024 Jan-Dec. Neurooncol Adv. 2024. PMID: 39233831 Free PMC article.
[SFCE harmonization workshops: Neonatal acute myeloid leukemia].
Ducassou S, Abou Chahla W, Duployez N, Halfon-Domenech C, Brethon B, Poirée M, Adam de Beaumais T, Lemaître L, Sirvent N, Petit A. Ducassou S, et al. Among authors: adam de beaumais t. Bull Cancer. 2024 May;111(5):513-524. doi: 10.1016/j.bulcan.2023.12.010. Epub 2024 Mar 19. Bull Cancer. 2024. PMID: 38503585 Review. French.
Clinical trial inclusion in patients with relapsed/refractory neuroblastoma following the European Precision Cancer Medicine trial MAPPYACTS.
Chaix J, Schleiermacher G, Corradini N, André N, Thebaud E, Gambart M, Defachelles AS, Entz-Werle N, Chastagner P, De Carli É, Ducassou S, Landman-Parker J, Adam-de-Beaumais T, Larive A, Michiels S, Vassal G, Valteau-Couanet D, Geoerger B, Berlanga P. Chaix J, et al. Among authors: adam de beaumais t. Eur J Cancer. 2024 Apr;201:113923. doi: 10.1016/j.ejca.2024.113923. Epub 2024 Feb 15. Eur J Cancer. 2024. PMID: 38377775
Neurofibromatosis type 1 mosaicism in patients with constitutional mismatch repair deficiency.
Guerrini-Rousseau L, Pasmant E, Muleris M, Abbou S, Adam-De-Beaumais T, Brugieres L, Cabaret O, Colas C, Cotteret S, Decq P, Dufour C, Guillerm E, Rouleau E, Varlet P, Zili S, Vidaud D, Grill J. Guerrini-Rousseau L, et al. Among authors: adam de beaumais t. J Med Genet. 2024 Jan 19;61(2):158-162. doi: 10.1136/jmg-2023-109235. J Med Genet. 2024. PMID: 37775264 Free PMC article.
Longitudinal characterization of primary osteosarcoma and derived subcutaneous and orthotopic relapsed patient-derived xenograft models.
da Costa MEM, Droit R, Khneisser P, Gomez-Brouchet A, Adam-de-Beaumais T, Nolla M, Signolles N, Torrejon J, Lombard B, Loew D, Ayrault O, Scoazec JY, Geoerger B, Vassal G, Marchais A, Gaspar N. da Costa MEM, et al. Among authors: adam de beaumais t. Front Oncol. 2023 Jun 12;13:1166063. doi: 10.3389/fonc.2023.1166063. eCollection 2023. Front Oncol. 2023. PMID: 37377921 Free PMC article.
A loss-of-function IFNAR1 allele in Polynesia underlies severe viral diseases in homozygotes.
Bastard P, Hsiao KC, Zhang Q, Choin J, Best E, Chen J, Gervais A, Bizien L, Materna M, Harmant C, Roux M, Hawley NL, Weeks DE, McGarvey ST, Sandoval K, Barberena-Jonas C, Quinto-Cortés CD, Hagelberg E, Mentzer AJ, Robson K, Coulibaly B, Seeleuthner Y, Bigio B, Li Z, Uzé G, Pellegrini S, Lorenzo L, Sbihi Z, Latour S, Besnard M, Adam de Beaumais T, Jacqz Aigrain E, Béziat V, Deka R, Esera Tulifau L, Viali S, Reupena MS, Naseri T, McNaughton P, Sarkozy V, Peake J, Blincoe A, Primhak S, Stables S, Gibson K, Woon ST, Drake KM, Hill AVS, Chan CY, King R, Ameratunga R, Teiti I, Aubry M, Cao-Lormeau VM, Tangye SG, Zhang SY, Jouanguy E, Gray P, Abel L, Moreno-Estrada A, Minster RL, Quintana-Murci L, Wood AC, Casanova JL. Bastard P, et al. Among authors: adam de beaumais t. J Exp Med. 2022 Jun 6;219(6):e20220028. doi: 10.1084/jem.20220028. Epub 2022 Apr 20. J Exp Med. 2022. PMID: 35442418 Free PMC article.
The European MAPPYACTS Trial: Precision Medicine Program in Pediatric and Adolescent Patients with Recurrent Malignancies.
Berlanga P, Pierron G, Lacroix L, Chicard M, Adam de Beaumais T, Marchais A, Harttrampf AC, Iddir Y, Larive A, Soriano Fernandez A, Hezam I, Chevassus C, Bernard V, Cotteret S, Scoazec JY, Gauthier A, Abbou S, Corradini N, André N, Aerts I, Thebaud E, Casanova M, Owens C, Hladun-Alvaro R, Michiels S, Delattre O, Vassal G, Schleiermacher G, Geoerger B. Berlanga P, et al. Among authors: adam de beaumais t. Cancer Discov. 2022 May 2;12(5):1266-1281. doi: 10.1158/2159-8290.CD-21-1136. Cancer Discov. 2022. PMID: 35292802 Free PMC article.
NTRK Alterations in Pediatric High-Risk Malignancies Identified Through European Clinical Sequencing Programs Constitute Promising Drug Targets.
Pfaff E, Adam de Beaumais T, Marchais A, van Tilburg CM, Blattner-Johnson M, Dirksen U, Øra I, Geoerger B, Schleiermacher G, Pfister SM, Witt O, Jones DTW, Vassal G. Pfaff E, et al. Among authors: adam de beaumais t. JCO Precis Oncol. 2021 Nov;5:450-454. doi: 10.1200/PO.20.00417. JCO Precis Oncol. 2021. PMID: 34994601 No abstract available.
Pharmacogenetics: Applications to Pediatric Patients.
Adam de Beaumais T, Jacqz-Aigrain E. Adam de Beaumais T, et al. Adv Pharmacol. 2018;83:191-215. doi: 10.1016/bs.apha.2018.04.006. Epub 2018 May 17. Adv Pharmacol. 2018. PMID: 29801575 Review.
16 results